Golidocitinib for rapidly worsening lung disease
Part of Lungs & breathing clinical trials.
This study tests an investigational pill (golidocitinib) for people whose interstitial lung disease is getting worse quickly, despite needing steroids. The goal is to see if this drug can help slow or stop the rapid decline in lung function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your lung disease has worsened quickly in the past month, with new symptoms and CT scan changes.
- You have low blood oxygen levels or a significant drop in lung function tests.
- You have not taken JAK inhibitor drugs before.
- You are not on a breathing machine or ECMO, and you are not pregnant or nursing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called nerandomilast to see if it can slow down early lung changes in people who have a close family member with a type of lung scarring called pulmonary fibrosis. You may join if you are 40 or older, have a parent, sibling, or child with this condition, and have early signs of lung changes on a CT scan.
This trial tests a combination of golidocitinib (a targeted pill) and a PD-1 inhibitor (a type of immunotherapy) as a maintenance treatment after initial chemotherapy. It may help keep your lung cancer from growing longer.
This trial tests a combination of two drugs for people with advanced non-small cell lung cancer. The drugs aim to help your immune system fight the cancer more effectively.
This study tests a new daily pill called golidocitinib for adults with immune thrombocytopenia (ITP) — a condition where the immune system attacks platelets, leading to low counts and bleeding risk. The drug aims to lower that immune attack and raise platelet counts, and may help people who have not had lasting success with other treatments.
This trial tests an oral JAK1 inhibitor called golidocitnib for people with T/NK-cell lymphoma that came back after treatment or didn't respond. The drug works by blocking a signal that helps cancer cells grow.
This trial tests two medications (golidocitinib and chidamide) for people with a type of lymphoma that affects the skin. The combo may help control the disease when other treatments haven't worked or have stopped working.
Hear when a new Interstitial Lung Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.